综合网络药理学和分子动力学揭示了Myrtus communis精油的多目标抗癌机制
Ahmed Bayoudh1, Nidhal Tarhouni1, Riadh Ben Mansour2
1Laboratory of Enzyme Engineering and Microbiology, Engineering National School of Sfax (ENIS), University of Sfax, P.O. Box 1173, Sfax 3038, Tunisia.
Pharmaceuticals (Basel, Switzerland)
|October 29, 2025
概括
突尼斯Myrtus communis精油 (McEOs) 通过向多个途径,表现出强大的抗癌活性,其中spathulenol作为强烈的雄激素受体对手,支持激素依赖癌症的潜力.
科学领域:
- 自然产品化学 自然产品化学
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症的复杂性需要针对多种致癌途径的多药学策略.
- 自然产品提供多样化的化学结构,用于多目标药物发现.
- 美公园精油 (McEOs) 具有抗癌应用的潜力.
研究的目的:
- 调查突尼斯MCEOs的抗癌机制.
- 阐明MCEOs的多药学基础和治疗潜力.
- 使用一个集成的计算-实验框架.
主要方法:
- 气相色谱-质谱 (GC-MS) 用于McEO组成分析.
- 针对HeLa,MCF-7和Raji癌细胞系的抗增殖活性进行MTT测定.
- 网络药理学,分子对接和分子动力学模拟用于机制阐明.
主要成果:
- 麦克欧含有丰富的1,8-基和基.
- 已证明的差异性细胞毒性:HeLa> MCF-7> Raji.
- 确定了spathulenol作为一种高亲和度的雄激素受体对手.
- 通过分子动力学证实了spathulenol-AR复合物的稳定性.
结论:
- 麦克欧通过协同作用来发挥多目标抗癌效应.
- 斯巴图伦醇具有强大的雄激素受体对抗作用,这对McEO的活性有很大影响.
- 验证了McEOs对荷尔蒙依赖性恶性瘤的治疗潜力.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K

